Bone Scintigraphy versus PSMA-Targeted PET/CT or PET/MRI in Prostate Cancer: Lessons Learned from Recent Systematic Reviews and Meta-Analyses

Dondi, Francesco; Albano, Domenico; Bertagna, Francesco; Treglia, Giorgio

doi:10.3390/cancers14184470

Cited by 10 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, PSMA-positron emission tomography (PET) has been shown to be more sensitive than bone scintigraphy in detecting bone metastases in patients with prostate cancer ( 70 ). High PSMA expression on planar/single-photon emission computed tomography (SPECT) or PET/CT scans following standard therapies for mCRPC, including 223 Ra, was associated with worse OS than low PSMA expression ( 71 ).…”

Section: Imagingmentioning

confidence: 99%

Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer

et al. 2022

View full text Add to dashboard Cite

Radium-223 dichloride (223Ra) is an α-emitter approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with bone metastases, but without visceral involvement. Despite being a life-prolonging therapy (LPT), 223Ra remains underutilized. A large body of real-world evidence (RWE) for 223Ra has been published in the decade since the pivotal phase 3 ALSYMPCA study, a period during which the treatment landscape has continued to evolve. How to optimize 223Ra use, including how to integrate it into the mCRPC management pathway amongst other current LPTs (i.e., with respect to timing and concurrent, layered, or sequential use), is therefore of considerable interest. RWE studies lack the conventional restraints of clinical trials and can therefore help to build an understanding of how treatments may be best used in routine practice. Here we review RWE studies investigating the efficacy and safety of 223Ra in mCRPC [including in sequence with the recently approved 177-Lutetium conjugated to the ligand prostate-specific membrane antigen (177Lu-PSMA)], as well as response marker development, imaging techniques, and current clinical practice recommendations.

show abstract

Section: Imagingmentioning

confidence: 99%

Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In particular, this is a clear and established modality with an important value for the follow-up of PCa subjects and its ability to possibly influence the management strategy of these patients has been underlined. In this setting, PSMA PET imaging has a prominent role in assessing PCa at both staging and restaging but also in the assessment of therapeutic response [ 8 , 9 , 28 ]. Therefore, its value for the guidance of AS has been studied in different papers.…”

Section: Discussionmentioning

confidence: 99%

“…In this setting, many different imaging modalities can be used to evaluate these subjects, starting from multiparametric magnetic resonance imaging (mpMRI) which has been recognized as the most precise imaging method for PCa detection and for T stage assignment [ 6 , 7 ]. More recently, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging performed with both PET/MRI or PET/CT tomographs has emerged as a promising and useful modality for both staging and restaging settings of PCa patients, as well as for the assessment of therapeutic response and therefore of prognosis prediction [ 8 , 9 , 10 , 11 ]. In particular, it has been underlined that PSMA PET/CT is a promising tool in the management of low- to intermediate-risk PCa, improving risk stratification and identifying patients at risk of pathological upstaging [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

The Role of PSMA PET Imaging in the Classification of the Risk of Prostate Cancer Patients: A Systematic Review on the Insights to Guide an Active Surveillance Approach

Dondi,

Antonelli,

Suardi

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

Background: active surveillance (AS) is a suitable strategy for patients with prostate cancer (PCa). Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging is an established tool used to assess PCa. The aim of this review was to evaluate the role of PSMA imaging to guide correct risk-based classification and the AS approach in PCa patients. Methods: The Scopus, Embase, Web of Science, Cochrane Library, and PubMed/MEDLINE databases were screened to find relevant published articles. Results: 1774 articles were revealed with the literature search. A total of 1764 articles were excluded after applying exclusion criteria (data not within the field of interest, preclinical papers, conference proceedings, reviews, or editorials). Ten studies were finally included in the review, revealing that PSMA PET could have the ability to guide risk-based classification of PCa and the choice of AS, and to guide the execution of biopsies for the research of high-grade PCa, therefore precluding AS. Conclusion: this systematic review underlined a possible role of PSMA PET imaging in patients with PCa by correctly re-classifying them on the basis of their risk and guiding AS.

show abstract

“…Lower PSA levels are indicative of reduced malignant activity and bone cell turnover thereby diminishing the diagnostic efficacy of BS. Consequently, certain studies advise against the utilization of BS in patients with PSA levels ranging from <10 ng/mL to 20 ng/mL [ 1 , 3 , 10 , 13 ].…”

Section: Discussionmentioning

confidence: 99%

Gradual normalization of superscan in prostate cancer: A case report and literature review

Ogu,

Jayasekera,

Villanueva-Meyer

et al. 2023

Radiology Case Reports

View full text Add to dashboard Cite

Bone Scintigraphy versus PSMA-Targeted PET/CT or PET/MRI in Prostate Cancer: Lessons Learned from Recent Systematic Reviews and Meta-Analyses

Abstract: Positron emission tomography (PET) combined with computed tomography (PET/CT) or magnetic resonance imaging (PET/MRI) using several radiopharmaceuticals [...]

Cited by 10 publications

References 22 publications

Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer

Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer

The Role of PSMA PET Imaging in the Classification of the Risk of Prostate Cancer Patients: A Systematic Review on the Insights to Guide an Active Surveillance Approach

Gradual normalization of superscan in prostate cancer: A case report and literature review

Contact Info

Product

Resources

About